Burden of disease attributable to second-hand smoke exposure: A systematic review.

Burden of disease Population attributable fraction Second-hand smoke Systematic review Tobacco

Journal

Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116

Informations de publication

Date de publication:
12 2019
Historique:
received: 12 04 2019
revised: 30 08 2019
accepted: 05 09 2019
pubmed: 11 9 2019
medline: 21 8 2020
entrez: 11 9 2019
Statut: ppublish

Résumé

Our aim was to provide a systematic review of studies on the burden of disease due to second-hand smoke (SHS) exposure, reviewing methods, exposure assessment, diseases causally linked to SHS, health outcomes, and estimates available to date. A literature review of studies on the burden of disease from SHS exposure, available in PubMed and SCOPUS, published 2007-2018 in English language, was carried out following the PRISMA recommendations. Overall, 588 studies were first identified, and 94 were eligible. Seventy-two studies were included in the systematic review. Most of them were based on the comparative risk assessment approach, assessing SHS exposure using mainly surveys on exposure at home/workplaces. Diseases more frequently studied were: lung cancer, ischemic heart disease, stroke, chronic obstructive pulmonary disease, asthma and breast cancer in adults; lower respiratory tract infection, otitis media, asthma, sudden infant death syndrome and low birth weight in children. The SHS exposure assessment and the reported population attributable fractions (PAF) were largely heterogeneous. As an example, the PAF from lung cancer varied between 0.6% and 20.5%. Moreover, PAF were estimated applying relative risks and SHS exposures with no consistent definitions or with different age classes. The research gap on the SHS exposure burden is shrinking. However, estimates are not yet available for a number of countries, particularly the Middle Eastern and African countries, and not all diseases with the strongest evidence of causation, such as sudden infant death syndrome, have been explored. Moreover, in some cases the applied methodology revealed relatively low quality of data.

Identifiants

pubmed: 31505203
pii: S0091-7435(19)30309-3
doi: 10.1016/j.ypmed.2019.105833
pii:
doi:

Substances chimiques

Tobacco Smoke Pollution 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

105833

Investigateurs

Yolanda Castellano (Y)
Marcela Fu (M)
Montse Ballbè (M)
Beladenta Amalia (B)
Olena Tigova (O)
Xavier Continente (X)
Teresa Arechavala (T)
Elisabet Henderson (E)
Alessandra Lugo (A)
Xiaoqiu Liu (X)
Cristina Bosetti (C)
Enrico Davoli (E)
Paolo Colombo (P)
Rachel O'Donnell (R)
Ruaraidh Dobson (R)
Luke Clancy (L)
Sheila Keogan (S)
Hannah Byrne (H)
Panagiotis Behrakis (P)
Anna Tzortzi (A)
Constantine Vardavas (C)
Vergina Konstantina Vyzikidou (VK)
Gerasimos Bakellas (G)
George Mattiampa (G)
Roberto Boffi (R)
Ario Ruprecht (A)
Cinzia De Marco (C)
Alessandro Borgini (A)
Chiara Veronese (C)
Martina Bertoldi (M)
Andrea Tittarelli (A)
Simona Verdi (S)
Elisabetta Chellini (E)
Marta Trapero-Bertran (M)
Daniel Celdrán Guerrero (DC)
Cornel Radu-Loghin (C)
Dominick Nguyen (D)
Polina Starchenko (P)
Julio Ancochea (J)
Tamara Alonso (T)
María Teresa Pastor (MT)
Marta Erro (M)
Ana Roca (A)
Patricia Pérez (P)

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Giulia Carreras (G)

Oncologic Network, Prevention and Research Institute (ISPRO), via Cosimo il Vecchio 2, 50139 Florence, Italy. Electronic address: g.carreras@ispro.toscana.it.

Alessandra Lugo (A)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS (IRFMN), Via La Masa 19, 20156 Milan, Italy.

Silvano Gallus (S)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS (IRFMN), Via La Masa 19, 20156 Milan, Italy.

Barbara Cortini (B)

Oncologic Network, Prevention and Research Institute (ISPRO), via Cosimo il Vecchio 2, 50139 Florence, Italy.

Esteve Fernández (E)

Catalan Institute of Oncology (ICO), Granvia de L'Hospitalet, 199-203, PC 08908 L'Hospitalet de Llobregat, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Granvia de L'Hospitalet, 199, PC 08908 L'Hospitalet de Llobregat, Spain; Department of Clinical Sciences, Campus de Bellvitge, School of Medicine and Health Sciences, University of Barcelona, Feixa Llarga, s/n, PC 08907 L'Hospitalet de Llobregat, Spain.

Maria José López (MJ)

Public Health Agency of Barcelona (ASPB). Pl. Lesseps, 1, PC 08023 Barcelona, Spain; CIBER Epidemiologia y Salud Pública (CIBERESP), Av. Monforte de Lemos, 3-5, Pabellón 11, Planta 0. PC 28029, Madrid, Spain; Institut d'Investigació Biomèdica de Sant Pau (IIB Sant Pau), Sant Antoni Maria Claret, 167, PC 08025 Barcelona, Spain.

Joan B Soriano (JB)

Hospital Universitario La Princesa (IISP), Diego de León, 62 1st floor, PC 28006 Madrid, Spain.

Angel López-Nicolás (A)

Polytechnic University of Cartagena (UPCT), Plaza Cronista Isidoro Valverde, s/n, PC 30202 Cartagena, Spain.

Sean Semple (S)

Faculty of Health Sciences and Sport, University of Stirling, Stirling FK9 4LA, Scotland, UK.

Giuseppe Gorini (G)

Oncologic Network, Prevention and Research Institute (ISPRO), via Cosimo il Vecchio 2, 50139 Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH